Medical Device Definition under Article 262 of the LGS

1. Key takeaways

Mexican law treats health supplies as the umbrella concept, and medical devices form one category within it, enumerated by Article 262 of the LGS as eight categories: medical equipment, prostheses, orthoses, functional aids, diagnostic agents, dental supplies, surgical and wound-care materials, and hygiene supplies. To determine whether a product is a medical device, first check whether its intended use falls within the statutory statements of use, and then check whether it can be placed into one of the eight categories. This two-step reasoning matters because Mexican law does not use a single catch-all definition like some other jurisdictions; the scope of regulation is anchored in an explicit list of categories, each with its own statutory description. A product that fits the statutory purpose language but resists categorization still needs careful analysis, while a product that fits a category cleanly can proceed to risk classification with confidence. Getting this determination right at the start prevents rework in the dossier, the labeling and the fee category later in the project.

2. Legal basis

The definitional framework is spread across the law, a technical standard and the pharmacopeial supplement, each contributing a different element. The table below maps the sources.

Taken together, these sources answer three different questions: Article 262 defines what kinds of products are regulated, Article 262 Bis defines what happens after authorization, and the standard and the supplement define how modern product types, including software, fit into the traditional device framework. A classification report that cites all of them in the correct roles is far more robust than one that relies on the law alone. When a reviewer questions the scope of the analysis, each citation points to a different layer of the framework, which makes the discussion faster and the outcome more predictable.

3. Expert insights

Insight 1: Computer programs were already in the definition. The definition in item 3.31 of NOM-241-SSA1-2021 already includes computer programs necessary for the proper use or application of the device, and the FEUM supplement version 5.0 (2023) went further by writing standalone software into the device definition. Companies frequently assume that Mexico does not regulate software, and this is a misjudgment. A mobile application that drives a device, a program needed to operate equipment, or software that performs a diagnostic function on its own all need evaluation under the Mexican framework. The practical consequence is that software scoping should happen at the same early stage as hardware scoping, not as an afterthought when the dossier is nearly complete.

Insight 2: Definition and classification live in different instruments. The categories are given by LGS Article 262, the risk classes are given by RIS Articles 83 and 83 Bis, and the detailed rules are given by the 23 rules of the FEUM supplement. The three layers apply cumulatively, not as alternatives: you cannot use the classification rules to escape the statutory categories, and you cannot use the statutory categories to skip the risk classification. A sound dossier shows all three layers explicitly, so a reviewer can follow the path from product description to category, from category to class, and from class to the specific rule that clinches the result.

Insight 3: The 2026 amendment wrote post-market surveillance into the law. Article 262 Bis of the LGS was added by the amendment decree published in DOF 2026-01-15, elevating post-market surveillance from guidance-level recommendation to a statutory requirement, and stating expressly that surveillance activities must begin from the date COFEPRIS issues the registration. For a product that reaches the market upon registration, this obligation is effective immediately — there is no grace period and no trigger event later in the lifecycle. Companies should align their vigilance procedures, their registration holder agreements and their internal launch plans to this starting point.

Insight 4: Health supplies and medical device are not interchangeable terms. It is easy to conflate the two, but in the LGS the term health supplies is the umbrella concept covering drugs, devices and other supplies. If a contract, an authorization letter or a technical agreement refers only to health supplies, the scope becomes uncontrolled: it may sweep in products that were never intended, or fail to specify the device obligations that matter. Drafting should always name the device category and the specific product so the legal scope matches the commercial reality.

4. Practical recommendations

1. Structure the product determination as a three-part analysis of intended use, statutory category and risk class, citing a legal source for each part so the conclusion is traceable end to end.
2. Determine software products under the FEUM supplement version 5.0 approach, and assign their class using the supplement classification rules rather than by analogy to hardware.
3. For borderline products such as laboratory reagents and hospital furniture, check Annex III of the 2025 agreement first: that instrument expressly excludes 1,984 items from the definition of health supplies, and the product may already be out of scope.
4. Record the determination in the classification section of the registration dossier, keeping it consistent with the intended use stated on the label.

5. Verification checklist

• □ Confirmed that the product falls within one of the eight categories of LGS Article 262
• □ Software products assessed under FEUM supplement version 5.0 (2023)
• □ Start date of the post-market surveillance obligation under LGS Article 262 Bis recorded
• □ Checked whether the product is among the Annex III exclusions of the 2025 agreement
• □ Determination consistent with the intended use on the label

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com